https://www.selleckchem.com/pr....oducts/3-3-cgamp.htm
Optimal non-invasive biomarkers for diagnosis and treatment of nonalcoholic fatty liver disease (NAFLD) remain to be identified. To identify potential DNA methylation biomarkers for NAFLD. Genome-wide DNA methylation profiling was performed to identify differentially methylated CpG sites in peripheral blood leukocytes. Differentially methylated regions were validated using the MassCLEAVE assay. The expression levels of candidate genes were explored by Gene Expression Omnibus database. The hypomethylation of PRKCE CpG 4.5 and CpG 18.19
Like
Comment
Share
